Pyxis Oncology (NASDAQ:PYXS) Stock Price Target Raised at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its price target on Pyxis Oncology from $6 to $7 and maintained an “outperform” rating, implying 315.43% upside from the cited share price.
• Analyst views are mostly positive but mixed: seven analysts rate PYXS Buy and one rates it Sell; the consensus is “Moderate Buy” with an $8.71 price target.
• Pyxis reported a quarterly loss of $0.24 per share, narrower than analysts’ expected loss of $0.27 per share.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) had its price objective increased by research analysts at Royal Bank Of Canada from $6.00 to $7.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective indicates a potential upside of 315.43% from the company's current price.

PYXS has been the subject of several other reports. HC Wainwright raised their price objective on shares of Pyxis Oncology from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. Weiss Ratings reissued a "sell (e+)" rating on shares of Pyxis Oncology in a report on Friday, September 25th. Wells Fargo & Company increased their target price on Pyxis Oncology from $12.00 to $19.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 9th. Stifel Nicolaus set a $5.00 price target on Pyxis Oncology in a report on Thursday. Finally, Wedbush reduced their price target on Pyxis Oncology from $8.00 to $7.00 and set an "outperform" rating for the company in a research report on Friday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $8.71.

Pyxis Oncology Stock Up 4.7%

PYXS traded up $0.07 during trading hours on Friday, hitting $1.69. The stock had a trading volume of 303,031 shares, compared to its average volume of 904,633. Pyxis Oncology has a 1 year low of $1.03 and a 1 year high of $5.55. The company's fifty day simple moving average is $2.54 and its 200 day simple moving average is $2.16. The stock has a market cap of $140.54 million, a PE ratio of -1.20 and a beta of 1.41.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. As a group, equities analysts expect that Pyxis Oncology will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC lifted its holdings in shares of Pyxis Oncology by 14.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company's stock worth $114,000 after acquiring an additional 6,295 shares during the last quarter. T3 Companies LLC bought a new position in shares of Pyxis Oncology during the 3rd quarter valued at $61,000. Finally, Renaissance Technologies LLC raised its position in Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company's stock worth $1,297,000 after purchasing an additional 160,300 shares during the period. 39.07% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology's pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.